ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral and inflammatory disease.
Quote | Abivax SA (OTCMKTS:AAVXF)
Last: | $10.95 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $10.95 |
High: | $0 |
Low: | $0 |
Volume: | 80 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Abivax SA (OTCMKTS:AAVXF)
2024-04-08 13:25:24 ET ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Conference Call April 08, 2024, 08:30 AM ET Company Participants Patrick Malloy - SVP, IR Marc de Garidel - CEO Sheldon Sloan - Chief Medical Officer Didier Scherrer - Chief Scie...
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients...
Message Board Posts | Abivax SA (OTCMKTS:AAVXF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Abivax SA Company Name:
AAVXF Stock Symbol:
OTCMKTS Market:
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients...
PARIS, FRANCE / ACCESSWIRE / October 24, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in p...
PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patie...